The effect of smoking on clinical and structural damage in patients with axial spondyloarthritis: A systematic literature review

Villaverde-García, Virginia; Cobo‐Ibáñez, Tatiana; Candelas-Rodríguez, Gloria; Seoane‐Mato, Daniel; Campo-Fontecha, Petra Díaz del; Guerra, Mercedes; Muñóz-Fernández, Santiago; Cañete, Juan D.

doi:10.1016/j.semarthrit.2016.11.004

Cited by 54 publications

(40 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Worse disease outcomes in females have also been demonstrated in other rheumatic diseases, with most evidence for this in RA and psoriatic arthritis. Smoking was associated with worse functional ability, an observation supported by other studies and suggested to be through an impact on structural damage progression . Furthermore, in fully adjusted models, worse functional ability was associated with worse quality of life, lower employment rates, and worse work productivity.…”

Section: Discussionsupporting

confidence: 76%

Association of Comorbidities in Spondyloarthritis With Poor Function, Work Disability, and Quality of Life: Results From the Assessment of SpondyloArthritis International Society Comorbidities in Spondyloarthritis Study

Nikiphorou

Ramiro

Heijde

et al. 2018

Arthritis Care & Research

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 76%

Association of Comorbidities in Spondyloarthritis With Poor Function, Work Disability, and Quality of Life: Results From the Assessment of SpondyloArthritis International Society Comorbidities in Spondyloarthritis Study

Nikiphorou

Ramiro

Heijde

et al. 2018

Arthritis Care & Research

View full text Add to dashboard Cite

show abstract

“…Smoking is known to be a harmful factor in patients with AS, leading to worse outcomes, including radiographic damage . In connection with that, in our survey we found that smoking habit and COPD were more common in patients with AS.…”

Section: Discussionsupporting

confidence: 70%

Impact of Comorbidity on Physical Function in Patients With Ankylosing Spondylitis and Psoriatic Arthritis Attending Rheumatology Clinics: Results From a Cross‐Sectional Study

Fernández‐Carballido¹,

Martín-Martínez

García-Gómez

et al. 2020

Arthritis Care & Research

View full text Add to dashboard Cite

Objective. To evaluate the impact of comorbidities on physical function in patients with ankylosing spondylitis (AS) and psoriatic arthritis (PsA).Methods. This was a cross-sectional analysis of the baseline visit from the Cardiovascular in Rheumatology study. Multivariate models with physical function as the dependent variable (Bath Ankylosing Spondylitis Functional Index and Health Assessment Questionnaire for AS and PsA, respectively) were performed. Independent variables were a proxy for the Charlson Comorbidity Index (CCIp; range 0-27), sociodemographic data, disease activity (erythrocyte sedimentation rate [ESR] and Bath Ankylosing Spondylitis Disease Activity Index [BASDAI] in AS; Disease Activity Score in 28 joints [DAS28] using the ESR in PsA), disease duration, radiographic damage, and treatments. Results were reported as beta coefficients, 95% confidence intervals (95% CIs), and P values.Results. We included 738 patients with AS and 721 with PsA; 21% of patients had >1 comorbidity. Comorbidity burden (CCIp) was independently associated with worse adjusted physical function in patients with PsA (β = 0.11). Also, female sex (β = 0.14), disease duration (β = 0.01), disease activity (DAS28-ESR; β = 0.19), and the use of nonsteroidal antiinflammatory drugs (β = 0.09), glucocorticoids (β = 0.11), and biologics (β = 0.15) were associated with worse function in patients with PsA. A higher education level was associated with less disability (β = -0.14). In patients with AS, age (β = 0.03), disease activity (BASDAI; β = 0.81), radiographic damage (β = 0.61), and the use of biologics (β = 0.51) were independently associated with worse function on multivariate analyses, but CCIp was not.Conclusion. The presence of comorbidities in patients with PsA is independently associated with worse physical function. The detection and control of the comorbidities may yield an integral management of the disease.

show abstract

“…Non-smokers AS patients also achieved remission more frequently than smoker patients at the end of the study, in agreement to published data. Previous studies indicate that this factor has a dose-dependent impact on structural damage progression and in worse treatment response of SpA patients [38][39][40][41].…”

Section: Discussionmentioning

confidence: 99%

Factors associated with ASDAS remission in a long-term study of ankylosing spondylitis patients under tumor necrosis factor inhibitors

et al. 2018

View full text Add to dashboard Cite

Objective: To determine the clinical and demographic factors associated with disease remission and drug survival in patients with ankylosing spondylitis (AS) on TNF inhibitors. Methods: Data from a longitudinal electronic database of AS patients under anti-TNF therapy between June/2004 and August/2013. Demographic, clinical parameters, disease activity by ASDAS remission (< 1.3) and inactive/low (< 2.1) were analyzed to characterize reasons for drug survival and switching of anti-TNF. Results: Among 117 AS patients, 69 (59%) were prescribed only one anti-TNF, 48 (41%) switched to a second anti-TNF and 13 (11%) to a third anti-TNF. Considering ASDAS-CRP < 1.3, 31 (39%) patients were inactive at the end of the study. Non-switchers (P = 0.04), younger age (P = 0.004), non-smoking (P = 0.016), shorter disease duration (P = 0.047), more frequent use of SSZ (P = 0.037) and lower BASDAI (P = 0.027), BASMI (P = 0.034) and BASFI (P = 0.003) at baseline were associated with remission. In the multivariate analysis younger age (P = 0.016) and lower BASDAI (P = 0.032) remained as remission predictors. Conclusion: This study supports that ASDAS-CRP remission is an achievable goal not only for non-switchers but also for second anti-TNF, particularly in patients with younger age and lower BASDAI at baseline. Comedication and non-smoker status seems to have a beneficial effect in anti-TNF response in this population.

show abstract

The effect of smoking on clinical and structural damage in patients with axial spondyloarthritis: A systematic literature review

Cited by 54 publications

References 39 publications

Association of Comorbidities in Spondyloarthritis With Poor Function, Work Disability, and Quality of Life: Results From the Assessment of SpondyloArthritis International Society Comorbidities in Spondyloarthritis Study

Association of Comorbidities in Spondyloarthritis With Poor Function, Work Disability, and Quality of Life: Results From the Assessment of SpondyloArthritis International Society Comorbidities in Spondyloarthritis Study

Impact of Comorbidity on Physical Function in Patients With Ankylosing Spondylitis and Psoriatic Arthritis Attending Rheumatology Clinics: Results From a Cross‐Sectional Study

Factors associated with ASDAS remission in a long-term study of ankylosing spondylitis patients under tumor necrosis factor inhibitors

Contact Info

Product

Resources

About